Hypothesis

JNK2 activity drives a temporal shift in AP-1 dimer composition from c-Fos/c-Jun to Fra1/JunB, which stabilizes H2A.J incorporation at SASP promoters and locks in chronic inflammation independent of upstream mitochondrial ROS.

Rationale

• Mitochondrial ROS initiates JNK activation, but sustained JNK signaling in senescence may become ROS‑independent through autocrine SASP loops 1.
• JNK1 and JNK2 have opposing roles in inflammatory disease 2, yet their isoform‑specific contributions to SASP are unknown.
• H2A.J accumulation is required for robust inflammatory gene expression 4 and could be recruited by specific AP-1 dimers.
• CD36 initiates SASP via Src–p38–NF-κB 3, providing an early signal that may feed into JNK2‑dependent chromatin remodeling.

We propose that after the acute phase, JNK2 preferentially phosphorylates JunB and Fra1, promoting their dimerization and binding to AP‑1 sites enriched in H2A.J‑containing nucleosomes. This complex recruits histone acetyltransferases that maintain an open chromatin state, thereby preserving SASP transcription even when mitochondrial ROS declines.

Predictions

1. In senescent cells, JNK2 knock‑down (but not JNK1) will reduce Fra1/JunB dimer levels and decrease H2A.J occupancy at IL6 and IL8 promoters.
2. Pharmacological inhibition of JNK2 will cause a rapid loss of SASP factors without affecting p16^INK4a‑mediated growth arrest.
3. Overexpression of a phospho‑deficient JunB mutant will block the AP‑1 dimer switch and prevent H2A.J accumulation, resulting in a transient SASP that resolves despite persistent mitochondrial ROS.
4. Chromatin immunoprecipitation sequencing (ChIP‑seq) for Fra1/JunB and H2A.J will show coincident peaks at SASP enhancers that appear after 72 h of senescence induction and persist for >10 days.

Experimental Design

• Induce senescence in human fibroblasts using doxorubicin or IR.
• Perform time‑course (0, 24, 48, 72, 96 h, 7 d) western blots for phospho‑JNK1/2, c‑Fos, c‑Jun, Fra1, JunB.
• Use isoform‑specific siRNA or CRISPRi to deplete JNK1 or JNK2; assess SASP cytokine secretion (ELISA), H2A.J ChIP‑qPCR, and AP‑1 dimer composition via co‑immunoprecipitation.
• Treat cells with a JNK2‑selective inhibitor (e.g., CC‑930) vs JNK1 inhibitor; monitor growth arrest (SA‑β‑gal, p16) and SASP.
• Rescue experiments: overexpress wild‑type or phospho‑deficient JunB in JNK2‑depleted cells.
• Conduct ChIP‑seq for Fra1, JunB, H2A.J, and acetyl‑H3K27 at 48 h and 10 d.

Potential Outcomes

If the hypothesis is correct, JNK2 loss will specifically abolish the Fra1/JunB‑H2A.J chromatin module and convert a chronic SASP into a transient, ROS‑dependent response, while leaving growth arrest intact. Conversely, JNK1 depletion will diminish early NF‑κB activation but not affect the later AP‑1 switch. Failure to observe these isoform‑specific effects would falsify the model and suggest that sustained JNK activity relies on alternative mechanisms.

References

[1] Mitochondrial ROS drives JNK activation in senescent cells https://doi.org/10.1101/gad.331272.119 [2] JNK1 and JNK2 exhibit distinct, context‑dependent, and sometimes opposing functions in inflammatory disease https://pmc.ncbi.nlm.nih.gov/articles/PMC3181375/ [3] CD36 acts as an early initiator of SASP through Src–p38–NF‑κB signaling https://doi.org/10.15252/embr.201745274 [4] The histone variant H2A.J accumulates in senescent cells and is required for robust inflammatory gene expression https://doi.org/10.1038/ncomms14995 [5] A conserved transcriptional program dominated by NF‑κB/IL‑1 and interferon pathways characterizes both induced senescence and organismal aging https://doi.org/10.4161/15384101.2014.973327 [6] JNK1's pro‑inflammatory role versus JNK2's paradoxical protective effects in other contexts https://pmc.ncbi.nlm.nih.gov/articles/PMC2614457/